CAR T Cell Therapy Market Competition Analysis By Player's 2022 - Novartis AG, Gilead Sciences Inc., Celgene Corporation

The Car T Cell Therapy Market is expected to climb up the ladder of persistence in the next decade. With various healthcare apps on the anvil, there are also mindfulness apps being tabled. They fall in the category of "Wellness apps". With the world wishing for the post-Covid era to function smoothly, these wellness apps are expected to take the healthcare vertical by storm further.

According to a recent study by Persistence Market Research, the global CAR T-cell therapy market is anticipated to experience high growth over the coming years. The market is expected to grow from US$ 1.2 Bn in 2020 to over US$ 2.8 Bn by 2031, which reflects a CAGR of around 5.6% for the next ten years.

Key players in the CAR T-cell therapy space are focusing on acquisitions and collaborations with other players of the market to strengthen their position by offering a wide range of products.

For instance, in December 2017, Gilead Science acquired Cell Design Labs Inc., which is a privately held company of biotherapeutics that discovers and develops cell-based therapies. This acquisition benefits Gilead through gaining novel technology platforms that will its boost R&D efforts in cellular therapy.

Get Sample Copy of this Report@ https://www.persistencemarketresearch.com/samples/28264

Also, increasing number of clinical trials in the field of life sciences and CAR T-cells will benefit manufacturers and researchers in developing innovative cancer therapy. With a large extent of studies taking place around CAR T-cell therapy, it is anticipated to enhance product availability in the market over the coming years.

For instance, the experiment on AntiCD19 Chimeric Antigen Receptor T Cells for the treatment of relapsed or refractory Non-Hodgkin lymphoma by Benjamin Tomlinson is undergoing and is currently in phase I clinical trial.
Another study by Janssen Research & Development, LLC of a chimeric antigen receptor T Cell (CAR-T) therapy for myeloma is in phase 2 clinical trial.
Furthermore, a study on the safety and efficacy of ALLO-605 in patients with relapsed/refractory multiple myeloma by Allogene Therapeutics is currently in phase 2.

All these factors will drive demand for CAR T-cell therapy during the forecast period (2021 to 2031).

Company Profiles:

Novartis AG
Gilead Sciences Inc.
Celgene Corporation
bluebird bio, Inc.

Request for Methodology@ https://www.persistencemarketresearch.com/methodology/28264

Key Takeaways from Market Study

By product, Yescarta (axicabtagene ciloleucel) holds high share of approximately 59%.
By indication, relapsed large B-cell lymphoma accounts for approximately 93% market share.
By end user, cancer treatment centers account for around 92% share in the market.
By region, North America holds the largest share of 68.1% of the global CAR T-cell therapy market, due to increasing number of life science companies focusing on the development and commercial manufacturing of CAR T-cells in the region.
"Increasing prevalence of cancer and continuous R&D on cell-based therapies are expected to drive demand for CAR T-cell therapy over the decade," says a Persistence Market Research analyst.

Access Full Report@ https://www.persistencemarketresearch.com/checkout/28264

Who is Winning in This Space?

Many of the chief players in the CAR T-cell therapy market are focusing on product launches and collaborations for global expansion.

In March 2018, Celgene Corporation completed the acquisition of Juno Therapeutics, Inc. This acquisition helps Celgene advance in cellular immunotherapy by adding novel technology and advanced cellular manufacturing capabilities to its portfolio.
In August 2017, Gilead Science announced the acquisition of Kite Pharma Inc., an industry leader in the emerging field of cell therapy.
In March 2021, Kite Pharma gained FDA approval for axicabtagene ciloleucel (axi-cel), a CAR T-cell based therapy.

Want More Insights?

Persistence Market Research brings the comprehensive research report on forecasted revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2016 to 2031.

The market is segmented in detail based on product (Yescarta (axicabtagene ciloleucel), Kymriah (tisagenlecleucel), JCAR017 (lisocabtagene maraleucel), and bb2121) indication (Relapsed Large B-cell Lymphoma, Acute Lymphoblastic Leukemia (ALL), and Multiple Myeloma), and end user (hospitals and cancer treatment centers), across seven major regions of the world.

Media Contact:
Persistence Market Research
305 Broadway,7th Floor New York City, NY 10007 United States
Call +1-646-568-7751
Call +1 800-961-0353
sales@persistencemarketresearch.com

About us:

Persistence Market Research, as a 3rd-party research organization, does operate through an exclusive amalgamation of market research and data analytics for helping businesses ride high, irrespective of the turbulence faced on the account of financial/natural crunches.

This release was published on openPR.